2008
Reduction of Restraint and Seclusion Through Collaborative Problem Solving: A Five-Year Prospective Inpatient Study
Martin A, Krieg H, Esposito F, Stubbe D, Cardona L. Reduction of Restraint and Seclusion Through Collaborative Problem Solving: A Five-Year Prospective Inpatient Study. Psychiatric Services 2008, 59: 1406-1412. PMID: 19033167, DOI: 10.1176/ps.2008.59.12.1406.Peer-Reviewed Original ResearchConceptsMean durationRestraint useProspective inpatient studyChildren's psychiatric inpatient settingPsychiatric inpatient unitPsychiatric inpatient settingsUse of restraintsSeclusion eventsInpatient studySchool-aged childrenStaff injuriesInpatient settingInpatient unitPatient assaultsReduction of restraintsTherapeutic programClinical settingSeclusion useTransient increaseStudy periodFiscal year 2003ChildrenEarly phaseMonthsEpisodes
2005
Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study
BLAIR J, SCAHILL L, STATE M, MARTIN A. Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 2005, 44: 73-79. PMID: 15608546, DOI: 10.1097/01.chi.0000145372.61239.bb.Peer-Reviewed Original ResearchConceptsQTc intervalClose electrocardiographic monitoringMean QTc prolongationQTc-prolonging agentsOpen-label trialLonger QTc intervalsCurrent treatment standardsQRS complex widthZiprasidone dosePediatric outpatientsQTc prolongationElectrocardiographic changesElectrocardiographic monitoringProspective studyMean ageSafety profilePeak QTcHeart rateHigh dosesZiprasidoneTreatment standardsDoseDosesPreliminary findingsProlongation
2004
Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data
Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B. Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data. American Journal Of Psychiatry 2004, 161: 1125-1127. PMID: 15169706, DOI: 10.1176/appi.ajp.161.6.1125.Peer-Reviewed Original Research
2003
Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
Martin A, Koenig K, Anderson GM, Scahill L. Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of Autism And Developmental Disorders 2003, 33: 77-85. PMID: 12708582, DOI: 10.1023/a:1022234605695.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderSelective serotonin reuptake inhibitor responseOpen-label studyOpen-label trialLow-dose fluvoxamineDevelopmental disordersPremature discontinuationClinical responseFluvoxamine treatmentPartial respondersMean ageSerotonin levelsSelect childrenPubertal statusInhibitor responseBehavioral activationFluvoxamineChildrenFurther investigationDisordersTreatmentGender differencesAdolescentsSubjectsTolerability
1999
Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildDibenzothiazepinesHumansMaleProspective StudiesQuetiapine FumarateWeight GainConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks